134 related articles for article (PubMed ID: 25256037)
1. Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy.
Ferroni P; Roselli M; Riondino S; Guadagni F
J Thromb Haemost; 2014 Dec; 12(12):2049-53. PubMed ID: 25256037
[TBL] [Abstract][Full Text] [Related]
2. Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.
Ferroni P; Guadagni F; Laudisi A; Vergati M; Riondino S; Russo A; Davì G; Roselli M
Oncologist; 2014 May; 19(5):562-7. PubMed ID: 24710308
[TBL] [Abstract][Full Text] [Related]
3. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study.
Ferroni P; Martini F; Portarena I; Grenga I; Riondino S; La Farina F; Laudisi A; Guadagni F; Roselli M
Support Care Cancer; 2012 Nov; 20(11):2713-20. PubMed ID: 22322591
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.
Guadagni F; Riondino S; Formica V; Del Monte G; Morelli AM; Lucchetti J; Spila A; D'Alessandro R; Della-Morte D; Ferroni P; Roselli M
World J Gastroenterol; 2017 Jul; 23(28):5187-5195. PubMed ID: 28811713
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE).
Chamberlain AM; Folsom AR; Heckbert SR; Rosamond WD; Cushman M
Blood; 2008 Oct; 112(7):2675-80. PubMed ID: 18614761
[TBL] [Abstract][Full Text] [Related]
6. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
Ferroni P; Palmirotta R; Riondino S; De Marchis ML; Nardecchia A; Formica V; Guadagni F; Roselli M
Thromb Haemost; 2016 Jan; 115(1):143-51. PubMed ID: 26336029
[TBL] [Abstract][Full Text] [Related]
7. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.
Ferroni P; Martini F; Portarena I; Massimiani G; Riondino S; La Farina F; Mariotti S; Guadagni F; Roselli M
Clin Lung Cancer; 2012 Nov; 13(6):482-7. PubMed ID: 22591606
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
[TBL] [Abstract][Full Text] [Related]
9. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism.
Gran OV; Braekkan SK; Paulsen B; Skille H; Rosendaal FR; Hansen JB
J Thromb Haemost; 2017 Jul; 15(7):1361-1367. PubMed ID: 28440069
[TBL] [Abstract][Full Text] [Related]
10. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.
Kuderer NM; Culakova E; Lyman GH; Francis C; Falanga A; Khorana AA
Oncologist; 2016 Jul; 21(7):861-7. PubMed ID: 27125754
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.
Ferroni P; Riondino S; Formica V; Cereda V; Tosetto L; La Farina F; Valente MG; Vergati M; Guadagni F; Roselli M
Int J Cancer; 2015 Mar; 136(5):1234-40. PubMed ID: 25042739
[TBL] [Abstract][Full Text] [Related]
12. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).
Ay C; Simanek R; Vormittag R; Dunkler D; Alguel G; Koder S; Kornek G; Marosi C; Wagner O; Zielinski C; Pabinger I
Blood; 2008 Oct; 112(7):2703-8. PubMed ID: 18539899
[TBL] [Abstract][Full Text] [Related]
13. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
[TBL] [Abstract][Full Text] [Related]
14. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
15. Thrombosis risk and survival in cancer patients with elevated C-reactive protein.
Kanz R; Vukovich T; Vormittag R; Dunkler D; Ay C; Thaler J; Haselböck J; Scheithauer W; Zielinski C; Pabinger I
J Thromb Haemost; 2011 Jan; 9(1):57-63. PubMed ID: 20874781
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
Reitter EM; Kaider A; Ay C; Quehenberger P; Marosi C; Zielinski C; Pabinger I
J Thromb Haemost; 2016 Feb; 14(2):294-305. PubMed ID: 26662117
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer.
Vergati M; Della-Morte D; Ferroni P; Cereda V; Tosetto L; La Farina F; Guadagni F; Roselli M
Rejuvenation Res; 2013 Jun; 16(3):224-31. PubMed ID: 23521603
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
[TBL] [Abstract][Full Text] [Related]
20. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Kim JS; Kang EJ; Kim DS; Choi YJ; Lee SY; Kim HJ; Seo HY; Kim JS
BMC Cancer; 2018 Dec; 18(1):1260. PubMed ID: 30558603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
